The Oncology Institute, Inc. TOI EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from The Oncology Institute, Inc.’s reported figures.
Based on trailing twelve months.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s EBITDA margin?
- The Oncology Institute, Inc. (TOI) reported EBITDA margin of -4.7% in Q1 2026.
- How has The Oncology Institute, Inc.'s EBITDA margin changed year-over-year?
- The Oncology Institute, Inc.'s EBITDA margin increased by 57.9% year-over-year, from -11.3% to -4.7%.
- What is the long-term trend for The Oncology Institute, Inc.'s EBITDA margin?
- Over 5 years (2020 to 2025), The Oncology Institute, Inc.'s EBITDA margin has grown at a 16.7% compound annual growth rate (CAGR), from -2.7% to -5.8%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.